Cardiomyocyte marker expression in a human lymphocyte cell line using mouse cardiomyocyte extract

Area of Science:

• Regenerative Medicine
• Cardiovascular Biology
• Cell Biology

Background:

• Cell transplantation is a promising strategy for treating cardiac diseases.
• Embryonic, cord blood, and mesenchymal stem cells are potential sources for cell therapy.
• Technical limitations of stem cells necessitate exploring alternative cell sources, such as transdifferentiation.

Purpose of the Study:

• To investigate the potential of transdifferentiating human peripheral blood cells into cardiomyocytes.
• To explore lymphocytes as an alternative cell source for cardiac regenerative medicine.

Main Methods:

• A human B lymphocyte cell line (Raji) was treated with 5-aza-2-deoxycytidine and trichostatin A.
• Cells were permeabilized and exposed to adult mouse cardiomyocyte extract.
• Immunohistochemistry and flow cytometry were used to detect cardiomyocyte markers (myosin heavy chain, α-actinin, cardiac troponin T) after 10 days, 3 weeks, and 4 weeks.

Main Results:

• Immunocytochemistry and flow cytometry confirmed the expression of cardiomyocyte markers in treated lymphocytes after 3 and 4 weeks.
• Troponin T expression was observed in 3.53% of cells, and α-actinin in 3.11%.
• While some cells adhered loosely, significant morphological changes towards cardiomyocyte-like structures were not observed.

Conclusions:

• Human lymphocytes can be induced to express cardiomyocyte markers, suggesting potential for reprogramming.
• Lymphocytes represent a viable alternative cell source for future research in cardiac cell reprogramming and therapy.
• This study provides a foundation for developing novel therapeutic strategies for cardiac diseases using reprogrammed lymphocytes.